title: [Clinical evaluation of Divina in treatment of hormonal disturbances in women].
abstract: The aim of this study was the assessment of clinical efficacy during hormonal treatment with Divina among women with hormonal cycle disturbances. Divina is a estrogen-progesatagen drug containing 2 mg valerate estradiol and 10 mg medroxyprogesteron acetate. The influence on lipid profile, liver and kidney activity and glucose tolerance was assessed. The measurement of bone density was performed twice before and after 6 months of treatment with Divina.
authors.affiliation: Katedry i Kliniki Endokrynologii Ginekologicznej Akademii Medycznej w Poznaniu.
authors.forename: A
authors.initials: A
authors.lastname: Warenik-Szymankiewicz
authors.forename: B
authors.initials: B
authors.lastname: Halerz-Nowakowska
authors.forename: M
authors.initials: M
authors.lastname: Wiza
authors.forename: W
authors.initials: W
authors.lastname: Grotowski
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control; D004338:Drug Combinations; D004958:Estradiol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007668:Kidney / Q000378:metabolism; D050356:Lipid Metabolism; D008099:Liver / Q000378:metabolism; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008593:Menopause / Q000187:drug effects / Q000378:metabolism; D008599:Menstruation Disturbances / Q000188:drug therapy*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control
chemical_list: D001786:Blood Glucose; D004338:Drug Combinations; C087853:divina; D004958:Estradiol; D008525:Medroxyprogesterone